Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PLVAP | Q9BX97 | Plasmalemma vesicle-associated protein (Fenestrated endothelial-linked structure protein) (Plasmalemma vesicle protein 1) (PV-1) | Disease related genesHuman disease related genesPlasma proteins | 1 | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 8 | 0.50 | |||
| PTCA | Q14761 | Protein tyrosine phosphatase receptor type C-associated protein (PTPRC-associated protein) (CD45-associated protein) (CD45-AP) (Lymphocyte phosphatase-associated phosphoprotein) | Predicted intracellular proteins | 1 | Other mediation | 8 | 0.50 | |||
| TN13B | Q9Y275 | Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form] | Cancer-related genesCD markersFDA approved drug targets | 1 | Lupus erythematosusLymphomaMultiple myeloma | Adhesion and uptake mediationClinical-translation mediationImmune mediation | 8 | 0.50 | ||
| PCDA1 | Q9Y5I3 | Protocadherin alpha-1 (PCDH-alpha-1) | Predicted membrane proteinsPredicted secreted proteins | 1 | Adhesion and uptake mediation | 7 | 0.50 | |||
| TRML1 | Q86YW5 | Trem-like transcript 1 protein (TLT-1) (Triggering receptor expressed on myeloid cells-like protein 1) | Plasma proteinsPredicted membrane proteins | 1 | Immune mediationReceptor-signaling mediation | 7 | 0.50 | |||
| CD8B | P10966 | T-cell surface glycoprotein CD8 beta chain (CD antigen CD8b) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 6 | 0.50 | |||
| CNNM4 | Q6P4Q7 | Metal transporter CNNM4 (Ancient conserved domain-containing protein 4) (Cyclin-M4) | Disease related genesHuman disease related genesPotential drug targets | 3 | Fusion and delivery mediationMetabolism mediation | 6 | 0.50 | |||
| I17RB | Q9NRM6 | Interleukin-17 receptor B (IL-17 receptor B) (IL-17RB) (Cytokine receptor-like 4) (IL-17 receptor homolog 1) (IL-17Rh1) (IL17Rh1) (Interleukin-17B receptor) (IL-17B receptor) | Predicted membrane proteins | 1 | Immune mediation | 6 | 0.50 | |||
| ADCY9 | O60503 | Adenylate cyclase type 9 (EC 4.6.1.1) (ATP pyrophosphate-lyase 9) (Adenylate cyclase type IX) (ACIX) (Adenylyl cyclase 9) (AC9) | EnzymesMetabolic proteinsPredicted intracellular proteins | 12 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 5 | 0.50 | |||
| CD4 | P01730 | T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4) | CD markersDisease related genesFDA approved drug targets | 1 | Acute myeloid leukaemiaAsthmaHuman immunodeficiency virus disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| CD86 | P42081 | T-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4 counter-receptor B7.2) (FUN-1) (CD antigen CD86) | CD markersFDA approved drug targetsPredicted intracellular proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | |||
| DYSF | O75923 | Dysferlin (Dystrophy-associated fer-1-like protein) (Fer-1-like protein 1) | Disease related genesHuman disease related genesPotential drug targets | 1 | Muscular dystrophy | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | ||
| EPHB1 | P54762 | Ephrin type-B receptor 1 (EC 2.7.10.1) (ELK) (EPH tyrosine kinase 2) (EPH-like kinase 6) (EK6) (hEK6) (Neuronally-expressed EPH-related tyrosine kinase) (NET) (Tyrosine-protein kinase receptor EPH-2) | EnzymesPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | |||
| FZD6 | O60353 | Frizzled-6 (Fz-6) (hFz6) | Disease related genesG-protein coupled receptorsHuman disease related genes | 7 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | |||
| HCST | Q9UBK5 | Hematopoietic cell signal transducer (DNAX-activation protein 10) (Membrane protein DAP10) (Transmembrane adapter protein KAP10) | Predicted membrane proteins | 1 | Immune mediationReceptor-signaling mediation | 5 | 0.50 | |||
| ICOSL | O75144 | ICOS ligand (B7 homolog 2) (B7-H2) (B7-like protein Gl50) (B7-related protein 1) (B7RP-1) (CD antigen CD275) | CD markersPlasma proteinsPredicted intracellular proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | |||
| KCJ15 | Q99712 | ATP-sensitive inward rectifier potassium channel 15 (Inward rectifier K(+) channel Kir1.3) (Inward rectifier K(+) channel Kir4.2) (Potassium channel, inwardly rectifying subfamily J member 15) | FDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins | 2 | Clinical-translation mediationFusion and delivery mediation | 5 | 0.50 | |||
| KCNN3 | Q9UGI6 | Small conductance calcium-activated potassium channel protein 3 (SK3) (SKCa 3) (SKCa3) (KCa2.3) | Disease related genesFDA approved drug targetsHuman disease related genes | 6 | Myelopathy | Clinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| KELL | P23276 | Kell blood group glycoprotein (EC 3.4.24.-) (CD antigen CD238) | 1 | Fusion and delivery mediationImmune mediationMetabolism mediation | 5 | 0.50 | ||||
| NKG2D | P26718 | NKG2-D type II integral membrane protein (Killer cell lectin-like receptor subfamily K member 1) (NK cell receptor D) (NKG2-D-activating NK receptor) (CD antigen CD314) | Cancer-related genesCD markersPredicted membrane proteins | 1 | Acute myeloid leukaemiaColorectal cancerCrohn disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.50 | ||
| PCDG6 | Q9Y5G7 | Protocadherin gamma-A6 (PCDH-gamma-A6) | Predicted membrane proteins | 1 | Adhesion and uptake mediation | 5 | 0.50 | |||
| PCDG8 | Q9Y5G5 | Protocadherin gamma-A8 (PCDH-gamma-A8) | Predicted membrane proteins | 1 | Adhesion and uptake mediation | 5 | 0.50 | |||
| PRRT2 | Q7Z6L0 | Proline-rich transmembrane protein 2 (Dispanin subfamily B member 3) (DSPB3) | Disease related genesHuman disease related genesPotential drug targets | 1 | Fusion and delivery mediationReceptor-signaling mediation | 5 | 0.50 | |||
| S19A1 | P41440 | Reduced folate transporter (FOLT) (Cyclic dinucleotide:anion antiporter SLC19A1) (Folate:anion antiporter SLC19A1) (Intestinal folate carrier 1) (IFC-1) (Placental folate transporter) (Reduced folate carrier protein) (RFC) (hRFC) (Reduced folate transporter 1) (RFT-1) (Solute carrier family 19 member 1) (hSLC19A1) | Cancer-related genesDisease related genesMetabolic proteins | 12 | Folate deficiency anaemiaLeukaemiaNutritional deficiency | Clinical-translation mediationFusion and delivery mediationImmune mediation | 5 | 0.50 | ||
| S38A5 | Q8WUX1 | Sodium-coupled neutral amino acid transporter 5 (Solute carrier family 38 member 5) (System N transporter 2) | Metabolic proteinsPredicted membrane proteinsTransporters | 11 | Fusion and delivery mediation | 5 | 0.50 |